TheraRadar
← Back
Data updated: Mar 29, 2026

DECIPHERA PHARMS

OncologyGastroenterology
Pharma

DECIPHERA PHARMS is a pharmaceutical company focused on Oncology, Gastroenterology. Key products include QINLOCK.

2020
Since
2
Drugs
-
Trials
3
Approved (2yr)

Key Drugs

QINLOCK
ripretinib
BRAF 1 indications · 2020
ROMVIMZA
vimseltinib
CSF1R 1 indications · 2025

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

ROMVIMZA 2025-12-12
Labeling
QINLOCK 2025-05-06
Labeling
ROMVIMZA 2025-02-14
Type 1 - New Molecular Entity
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 67%
2 drugs
Gastroenterology 33%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Oncology, Gastroenterology
Gilead Sciences biotech
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology